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Keloids are benign dermal tumors, characterized by
overgrowth of lesions, invasiveness beyond the origi-
nal boundary of the insult, and recurrence of lesions.
The exact etiology is unknown, however. Our
hypothesis is that keloids are acquired as a result of
an abnormal or prolonged wound healing process,
with persistent proliferation and extracellular matrix
production of ®broblasts that should otherwise
discontinue in normal wound healing. In this study,
we examined the response of keloid ®broblasts to
proapoptotic signaling. Cell-permeable ceramide,
N-acetyl-D-sphingosine, induced apoptosis of dermal
®broblasts in a dose- and time-dependent manner,
which was detected by phase contrast microscopy,
¯uorescent microscopy, the TUNEL method, ¯ow
cytometric analysis, and WST-1 assay. In contrast,
keloid ®broblasts resisted apoptosis induced by
N-acetyl-D-sphingosine (percent survival with 40 mM
ceramide treatment for 12 h, normal versus keloid:
9.6% 6 6.6% vs 66.8% 6 5.5%). Western blotting ana-
lysis showed insulin-like growth factor I receptor
overexpression in keloid ®broblasts, but not in
normal ®broblasts. Exogenously added insulin-like
growth factor I enhanced the resistance of keloid
®broblasts to ceramide-induced apoptosis. Wort-
mannin, a phosphatidylinositol 3 kinase inhibitor,
suppressed the antiapoptotic action of insulin-like
growth factor I in keloid ®broblasts. Our results
suggest that keloid ®broblasts overexpressing
insulin-like growth factor I receptor are resistant to
apoptosis, thus allowing persistent proliferation and
production of excessive extracellular matrix. Key
words: programmed cell death/wound healing. J Invest
Dermatol 115:1065±1071, 2000
K
eloids are characterized by proliferation of dermal
®broblasts, overproduction of extracellular matrix by
dermal ®broblasts, invasiveness beyond the original
boundary of the insult, and recurrence, and are
classi®ed as benign dermal tumors (Tredget et al,
1997). Although a benign disorder, surgical resection of keloids is
contraindicated because of the likelihood of local invasion and
recurrence. Accordingly various conservative therapies have been
used such as steroid, tranilast, and pressure treatment, but de®nite
and effective therapy has not yet been established.
The normal wound healing process consists of three phases:
in¯ammation, proliferation, and remodeling. From the in¯amma-
tion phase to the proliferation phase, in¯ammatory cells and small
vessels as well as ®broblasts accumulate and proliferate. Fibroblasts
produce extracellular matrix such as collagen and ®bronectin, and
they form granulation tissue. In the late phase of wound healing,
both cellularity and extracellular matrix decrease and the granula-
tion tissue evolves into a mature scar. We speculated that
in¯ammation and proliferation phases are sustained in keloid
formation and keloid ®broblasts become more resistant to cell
elimination by some unknown mechanism.
In a previous study, we reported that keloids overexpress insulin-
like growth factor I receptor (IGF-IR), and the IGF-I-IGF-IR
signal mediates invasiveness of keloid ®broblasts (Yoshimoto et al,
1999). IGF-I is also a well-known major survival factor in the
serum (O'Connor, 1998) and protects ®broblasts from apoptosis
under a wide variety of conditions, including serum deprivation,
Fas ligand, tumor necrosis factor a (Ortiz et al, 1997),
chemotherapeutic drugs (Sell et al, 1995), and ceramide
(Gerritsen et al, 1998).
Ceramide is a lipid second messenger that is well known as a
mediator of extracellular signals. It is formed by cell membrane
sphingomyelin and in¯uences proapoptotic signal pathways
induced by various stimuli such as Fas antigen (Tepper et al,
1995), tumor necrosis factor a (Kaipia et al, 1996), chemother-
apeutic drugs (Jaffrezou et al, 1996), and radiation (Haimovitz,
1998), and can also induce apoptosis by itself. So we considered
that ceramide might be one of the key mediators for apoptosis and
chose it as the inducer in our experiments. In this study, we
determined the expression of IGF-IR in keloid ®broblasts and
investigated whether it in¯uences the response to proapoptotic
signaling by N-acetyl-D-sphingosine (C2 ceramide).
MATERIALS AND METHODS
Materials Keloid samples were obtained from three different Japanese
patients after surgical excision. Three normal skin samples were obtained from
three Japanese volunteers. Informed consent was obtained from each subject.
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Reagents C2 ceramide and dihydro-C2-ceramide were purchased from
Calbiochem (La Jolla, CA). They were dissolved in ethanol and used as
10 mM stock solution. Hoechst 33342 and propidium iodide (PI) were
purchased from Sigma Chemical (St. Louis, MO). Human recombinant
IGF-I was kindly provided by Fujisawa Pharmaceutical (Tokyo, Japan).
Wortmannin was purchased from Wako Pure Chemical (Osaka, Japan) and
dissolved in phosphate-buffered saline (PBS) as 100 mM stock solution. All
other chemicals and reagents were of the highest purity available from
commercial sources.
Cell cultures Primary cultures of dermal ®broblasts were established as
previously described (Arakawa et al, 1990). Explants were maintained in
Dulbecco's modi®ed Eagle's medium (DMEM) with 10% fetal bovine
serum (Gibco BRL, Life Technologies), 100 U per ml penicillin, and
100 mg per ml streptomycin at 37°C in a humidi®ed incubator with 5%
CO2. Fibroblasts at passages 3±7 were used in this study.
Western blot analysis for IGF-IR Expression of IGF-IR was also
detected by western blotting. Cells were washed twice in ice-cold PBS
before lysis in sodium dodecyl sulfate (SDS) sample buffer (62.5 mM Tris-
HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mM dithiothreitol, and 0.1%
bromophenol blue). The lysates were sonicated for 2 s, boiled for 5 min,
and then microcentrifuged for 5 min. The protein concentration of the
lysates was determined by the Bio-Rad assay. Proteins were separated on
7.5% SDS polyacrylamide gels and transferred to nitrocellulose membranes
(Hybond-p; Amersham, Arlington Heights, IL). The membranes were
preincubated with a blocking buffer [1 3 Tris-buffered saline (TBS), 0.1%
Tween-20, and 5% nonfat dry milk] overnight at 4°C. They were then
incubated with a primary antibody to IGF-IR (mouse monoclonal
antibody for a subunits of human IGF-IR; Santa Cruz Biotechnology)
with gentle agitation overnight at 4°C. They were washed three times with
TBS-T, and incubated with the secondary antibody (horseradish peroxidase
conjugated goat antimouse IgG; ABC kit, Vector Laboratories). Proteins
were detected by enhanced chemiluminescence (Pierce) using the protocol
provided by the supplier.
Induction and detection of cell death Dermal ®broblasts were
preincubated for 48 h with serum-free medium. In the next step various
concentrations of C2 ceramide were added and the ®broblasts were further
incubated for an additional 12 h. The cells were viewed with a Nikon phase
contrast microscope and then trypsinized and washed with PBS, ®xed with
2% glutaraldehyde, and stained with Hoechst 33342 (1 mM) and PI (1 mg
per ml). Specimens were analyzed with an Olympus BH-2 ¯uorescent
microscope.
Terminal-deoxynucleotidyl-transferase -mediated dUTP-biotin
nick end labeling (TUNEL) method For the detection of apoptosis,
the procedure is based upon the method described by Gavrieli et al (1992).
To investigate the response of dermal ®broblasts to C2 ceramide, cultures
reaching 80%±90% con¯uence in the complete medium were starved for
Figure 1. Upregulation of IGF-I receptor expression in keloid
®broblasts compared with normal ®broblasts. Immunoblotting of
IGF-IR a subunits. Total cell lysates were prepared from the three
independent strains of normal and keloid ®broblasts, and equal amounts of
proteins were subjected to 7.5% SDS-polyacrylamide gel electrophoresis
followed by western blotting against IGF-IR a subunits. Lanes 1±3, normal
®broblasts; lanes 4±6, keloid ®broblasts.
Figure 2. Dose-dependent induction of cell
death by C2 ceramide in normal and keloid
®broblasts. (a-f) Phase contrast microscopy of
dermal ®broblasts cultured with DMEM contain-
ing various concentrations of C2 ceramide for
12 h. (a-c) Normal ®broblasts treated with 0±
50 mM C2 ceramide; (d-f) keloid ®broblasts treated
with 0±50 mM C2 ceramide; g, normal ®broblasts
treated with ethanol only; (h) normal ®broblasts
treated with 50 mM dihydro-C2-ceramide; (i)
¯uorescent microscopy (Hoechst 33342) of normal
®broblasts cultured with DMEM containing
30 mM C2 ceramide for 12 h. Typical morpholo-
gic changes of apoptotic cells are observed among
normal ®broblasts (arrow). Magni®cations: (a±h)
3 40; (i) 3 200.
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48 h in serum-free DMEM. Then various concentrations of C2 ceramide
were added and the cultures were further incubated for an additional 6 h.
Apoptosis induction by C2 ceramide was detected in situ by the TUNEL
method, using the Apoptosis in situ Detection Kit (Wako, Osaka, Japan)
according to the manufacturer's protocol.
Flow cytometry For ¯ow cytometric analysis, cells (5 3 105) were ®xed
with 70% ethanol and washed with PBS. After preincubation with RNase
A (0.1 mg per ml) at 37°C, cells were stained with PI (25 mg per ml), and
0.1% bovine serum albumin was added. Fluorescence was measured by
using a FACScan ¯ow cytometer (Becton Dickinson, Mountain View,
CA).
Cell survival assay We also assessed cell survival by using a modi®ed
MTT assay, WST-1 assay, a colorimetric assay based on the cleavage of the
tetrazolium salt WST-1 to a formazan dye by the mitochondrial
dehydrogenase of viable cells. Fibroblasts suspended in DMEM
containing 10% fetal bovine serum were seeded at 5 3 103 cells per well
into 96-well plates. The cells were preincubated for 24 h with serum-free
medium at 37°C. The medium was replaced with DMEM containing C2
ceramide (0±50 mM) with or without IGF-I (100 ng per ml) for 0±48 h at
37°C. The ready-to-use WST-1 reagent was added to the cells during the
last 2 h and incubated at 37°C.
Statistical analysis All values were expressed as mean 6 SD of triplicate
samples and were representative of at least three experiments. Differences
between groups were examined for statistical signi®cance using analysis of
variance. A p-value less than 0.01 denoted the presence of a statistically
signi®cant difference.
RESULTS
Expression of IGF-IR on dermal ®broblasts In our previous
study, we reported that keloids overexpress IGF-IR (Yoshimoto
et al, 1999). In this study we used different strains of keloid and
normal dermal ®broblasts, however, and therefore we ®rst checked
the expression of IGF-IR in these cells. In western blotting, high
expression of IGF-IR was detected in three keloid ®broblast strains
(Fig 1, lanes 4±6) whereas only a relatively weak expression of IGF-
IR was present in three normal dermal ®broblast strains (Fig 1, lanes
1±3). These results con®rmed our earlier ®ndings (Yoshimoto et al,
1999).
Figure 3. Determination of apoptotic ®bro-
blasts by the TUNEL method in vitro. (a, b)
Normal ®broblasts treated with 30 and 50 mM C2
ceramide; (c, d) keloid ®broblasts treated with 30
and 50 mM C2 ceramide; (e) normal ®broblasts
with no treatment; (f) normal ®broblasts treated
with ethanol only; (g) normal ®broblasts treated
with 50 mM dihydro-C2-ceramide. Typical apop-
totic cells were observed in a concentration-de-
pendent manner by C2 ceramide in normal
®broblasts, but only few TUNEL-positive cells
were detected in keloid ®broblasts under the same
conditions. Magni®cations: 3100.
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C2-ceramide-induced apoptosis of dermal ®broblasts After
12 h of treatment, C2 ceramide induced a dose-dependent cell
death of primary cultured human dermal ®broblasts (Fig 2a-c). To
discriminate between apoptosis and necrosis, we examined the
DNA fragmentation of C2-ceramide-treated dermal ®broblasts by
¯uorescent microscopy analysis and the TUNEL method. In
¯uorescent microscopy, typical apoptotic cells were easily observed
in normal ®broblasts (Fig 2i), but necrotic cells were very rare.
From this result, we considered that C2 ceramide mainly induced
apoptosis but not necrosis in dermal ®broblasts within the range 10-
50 mM. In contrast, keloid ®broblasts were more resistant to C2-
ceramide-induced cell death compared with normal dermal
®broblasts and they maintained their original structure and
viability (Fig 2d-f). In the TUNEL method, normal ®broblasts
treated with C2 ceramide underwent apoptosis in a concentration-
dependent manner, but only few TUNEL-positive cells were
detected in keloid ®broblasts (Fig 3). FACScan analysis showed a
high proportion of apoptotic cells among normal ®broblasts
(48.61% 6 8.82%) (Fig 4a, b). In contrast, keloid ®broblasts
resisted apoptosis (7.76% 6 3.48%) and underwent G2 arrest
(Fig 4c, d). We also checked cell viability of dermal ®broblasts by
WST-1 assay. In this assay, C2 ceramide induced loss of viability in
normal dermal ®broblasts in a concentration- and time-dependent
manner, but keloid ®broblasts resisted loss of viability compared
with normal ®broblasts (Figs 5, 6).
IGF-I inhibits ceramide-induced apoptosis IGF-I is well
known as a major survival factor in serum and can protect cells
against apoptosis under a wide variety of conditions. In the next
step, we examined the effects of IGF-I on normal and keloid
®broblasts treated with C2 ceramide. IGF-I (100 ng per ml)
inhibited apoptosis of normal ®broblasts slightly, but the
protective effects were more marked in keloid ®broblasts (Fig 7).
Furthermore, the protective effect correlated with the level of IGF-
IR expression.
Phosphatidylinositol 3 kinase (PI3-kinase) mediates the
antiapoptotic signal of IGF-IR in keloid ®broblasts Finally,
we investigated the mechanisms of antiapoptotic effects of IGF-IR
in keloid ®broblasts. PI3-kinase and Akt are known to mediate the
antiapoptotic signal of IGF-IR in ®broblasts (Kulik et al, 1997). In
the next step, we used wortmannin as a PI3-kinase inhibitor and
examined its effect on the antiapoptotic inhibitory action of IGF-I
in keloid ®broblasts. Preincubation with 100 nM wortmannin
blocked the antiapoptotic signal of IGF-IR (Fig 8).
DISCUSSION
Apoptosis is de®ned as programmed cell death. It is a genetically
controlled process to eliminate cells in response to a variety of
stimuli and provides protection against cancer, viral infections,
cytotoxic drugs, and radiation as well as maintaining homeostasis
Figure 4. DNA contents of normal and ke-
loid ®broblasts after treatment with C2 cera-
mide. Cells were cultured with serum-free
DMEM for 24 h and incubated with DMEM con-
taining 25 mM C2 ceramide for 12 h. Following
nuclear staining with PI, ¯ow cytometric analysis
was performed as described in Materials and Meth-
ods. (a, b) Normal ®broblasts; (c, d) keloid ®bro-
blasts; (e, f) negative controls of normal ®broblasts.
Note the increased population of apoptotic cells
(48.61% 6 8.82%) in normal ®broblasts after 12 h.
In contrast, keloid ®broblasts underwent a G2 ar-
rest and resisted apoptosis (7.76% 6 3.48%).
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under physiologic conditions (Cuff et al, 1996; Blank et al, 1997;
Dixon et al, 1997; Kinloch et al, 1999). Apoptosis also plays an
important role in the wound healing process (Desmouliere et al,
1995), and this study provided clear evidence for the resistance of
keloid ®broblasts to apoptosis, as evidenced by increased cell
proliferation and decreased cell apoptosis. We also demonstrated
that such properties correlated with overexpression of IGF-IR on
keloid ®broblasts. To our knowledge, there are no previous reports
on the role of IGF-IR in the apoptosis of keloid ®broblasts, except
for one study on apoptosis in keloid tissues (Appleton et al, 1996).
In contrast to our ®ndings, the above study showed increased
apoptosis in keloid tissues by using in situ end labeling (the TUNEL
method). The exact explanation of the different ®ndings is not clear
at present. The number of TUNEL-positive cells relative to total
cell number might be low, however, because of the markedly high
cell density in keloid tissues. Also Appleton et al (1996) did not
provide any functional studies using a cell culture system.
In this study, western blotting analysis showed that the
expression of IGF-IR on keloid ®broblasts was 1.4±2.9 times
higher than that on normal ®broblasts. Furthermore, we also
demonstrated resistance of keloid ®broblasts to C2-ceramide-
induced apoptosis compared with normal dermal ®broblasts. The
addition of exogenous IGF-I enhanced the survival of keloid
®broblasts in a manner proportionate to IGF-IR expression.
Comparison of cells derived from null mice of the IGF-IR gene
with stable transfectants overexpressing the human IGF-IR
demonstrated the importance of IGF-IR expression in resisting
apoptosis (Nakamura et al, 1997). Although we did not examine the
acquisition of resistance in normal skin ®broblasts by IGF-IR
transfection, our results also suggest that the number of functional
IGF-IR is important in the regulation of antiapoptotic signals.
The antiapoptotic signal pathway of IGF-IR in ®broblasts and
other cells has already been reported (Datta et al, 1997; Kulik et al,
1997). PI3-kinase is a major effector for signaling by IGF-IR (De
Meyts et al, 1994; Carpenter and Cantley, 1996; Mendez et al,
1996; Myers and White, 1996). Furthermore, Akt is identi®ed as
the downstream component of survival signaling through PI3-
kinase (Kulik et al, 1997; Dudek et al, 1997; Kauffmann-Zeh et al,
1997; Kennedy et al, 1997; Khwaja et al, 1997), which is a
growth factor that regulates serine/threonine kinase. Furthermore,
Figure 5. Cell viability of normal and keloid
®broblasts following C2 ceramide treatment
± dose-response. Each of three primary culture
cell lines of normal and keloid ®broblasts seeded
at 5 3 105 cells per well into 96-well plates were
cultured with the indicated concentrations of C2
ceramide, and the cell viability was monitored by
WST-1 assay as described in Materials and Methods.
The dose-dependent effect of C2 ceramide on the
cell viability of normal and keloid ®broblasts 12 h
after incubation. Note that keloid ®broblasts were
still resistant with the 40 mM concentration of C2
ceramide even though the same dose of C2 cera-
mide strongly abolished the cell viability of normal
®broblasts.
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activated Akt provides a survival signal that protects cells from
apoptosis induced by various stresses. Bad, a proapoptotic member
of the bcl-2 family, was identi®ed as a substrate of Akt when the
intersection point of proapoptotic and antiapoptotic regulatory
cascades was investigated (Ladin et al, 1998; del Peso et al, 1997).
This signal pathway has been recognized as a major antiapoptotic
signal pathway for IGF-IR. Kulik et al reported the existence of a
survival signaling pathway downstream of PI3-kinase, Akt/PKB, in
®broblasts overexpressing the IGF-IR (Kulik and Weber, 1998). In
this study, wortmannin, a PI3-kinase inhibitor, completely blocked
the antiapoptotic effect of IGF-I and IGF-IR in keloid ®broblasts.
Thus, PI3-kinase may also play a major role in the antiapoptotic
signal pathway in keloid ®broblasts.
The underlying mechanisms for the increased number of IGF-
IR in keloid ®broblasts remain unclear at this stage. The expression
of IGF-IR gene is modulated by a number of physiologic and
pathologic factors, such as developmental stage, nutritional status,
hormones, growth disorders, and malignancy (Werner et al, 1995).
The tumor suppressor gene p53 is a regulatory factor of
transcription of IGF-IR gene. Wild-type p53 suppresses IGF-IR
promoter activity whereas mutant p53 stimulates IGF-IR gene
transcription (Werner et al, 1996). Sead et al (1998) analyzed p53
gene mutation in keloids using polymerase-chain-reaction-based
single-strand conformational polymorphism and DNA sequencing.
They found mutations in exon 4 of p53 gene in all samples (codon
72, CGC®CCC, arginine®proline). We also checked this
mutation of p53 gene; however, we could not ®nd such mutations
in any of our keloid samples (data not shown). Viral protein
interacts with p53 and changes the protein conformation to be
similar to that of mutant p53. It is possible that changes in keloid
p53 might occur without any genetic mutation.
In conclusion, we demonstrated in this study that keloid
®broblasts overexpress IGF-IR, resist proapoptotic signals, and
disturb the balance between cell death and proliferation in the
lesions, eventually producing excessive extracellular matrix, result-
ing in the unique pathologic features of keloid tissues. Identi®cation
of the factors responsible for controlling the expression of IGF-IR
and apoptotic signal in keloids may therefore allow the design of
novel therapies for the treatment of keloids.
Human recombinant IGF-I was a kind gift from Fujisawa Pharmaceutical Co.,
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